報價延遲最少15分鐘:2025/03/28 05:29 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.0085 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.34/-0.56
|
|
企業價值
1.34M
|
| 資產負債 |
|
每股賬面淨值
0.62
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 05:29 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development. |